<code id='3AB6083C81'></code><style id='3AB6083C81'></style>
    • <acronym id='3AB6083C81'></acronym>
      <center id='3AB6083C81'><center id='3AB6083C81'><tfoot id='3AB6083C81'></tfoot></center><abbr id='3AB6083C81'><dir id='3AB6083C81'><tfoot id='3AB6083C81'></tfoot><noframes id='3AB6083C81'>

    • <optgroup id='3AB6083C81'><strike id='3AB6083C81'><sup id='3AB6083C81'></sup></strike><code id='3AB6083C81'></code></optgroup>
        1. <b id='3AB6083C81'><label id='3AB6083C81'><select id='3AB6083C81'><dt id='3AB6083C81'><span id='3AB6083C81'></span></dt></select></label></b><u id='3AB6083C81'></u>
          <i id='3AB6083C81'><strike id='3AB6083C81'><tt id='3AB6083C81'><pre id='3AB6083C81'></pre></tt></strike></i>

          Home / comprehensive / explore

          explore


          explore

          author:hotspot    Page View:98883
          Franklin faces
          Adobe

          ARCH Venture Partners, one of the top investors in the biotech ecosystem, is raising $3 billion for a new fund.

          The Chicago-based firm filed paperwork with the Securities and Exchange Commission this week for what would be its 13th namesake fund. Arch estimated it would raise around $3 billion — roughly the same amount it raised during its more recent fundraising in 2022.

          advertisement

          Arch declined to comment on the new fundraising.

          Get unlimited access to award-winning journalism and exclusive events.

          Subscribe Log In